Akademik Veri Yönetim Sistemi
Electrochimica Acta, cilt.549, 2026 (SCI-Expanded, Scopus)
Cancer is a disease that impacts a significant portion of the global population, and delayed diagnosis complicates treatment and elevates mortality rates. The disease affects many organs and has many subtypes. Breast cancer is the most prevalent condition among women, and biomarkers are crucial for disease diagnosis. HER2 is a significant protein marker in breast cancer biomarkers; however, it is also present in healthy individuals, making its quantification essential for disease detection. This paper presents a readily fabricated, rapid-response MoO3-CTAB based immunosensor for the sensitive and selective detection of HER2. The sensor's efficiency during the preparation steps was assessed using differential pulse voltammetry (DPV) and cyclic voltammetry (CV) techniques. The DPV responses acquired from the designed sensor demonstrated a linear correlation with HER2 within the concentration range of 10 ng/mL to 125 ng/mL. The HER2 determination method yielded limit of detection (LOD) and limit of quantitation (LOQ) values of 2.85 ng/mL and 8.57 ng/mL, respectively. The immunosensor demonstrated significant selectivity against diverse interfering substances and effectively detected HER2 in commercial human serum samples, achieving recovery rates between 99.10% and 100.66%.